On October 14, 2020, the Dutch Healthcare Institute (ZIN) announced the evaluation of personalized medicine and molecular diagnostics for advice on reimbursement under Basic Health Insurance.
Personalized medicine is becoming increasingly important in the application of drugs. Molecular diagnostics makes it possible to predict the effects of medicine based on a patient's DNA. To ensure that this form of predictive diagnostics can be used everywhere in the Netherlands.
The assessment will be performed on the request of the Dutch Ministry of Health, Welfare, and Sport and will address the following issues:
- Which molecular diagnostics is needed in which phase of the disease?
- How can new technologies in this area get a place quickly when they have proven to be effective?
- How should molecular diagnostics be offered to ensure that it is accessible, to the right patient, at the right time?
- Define reimbursement pathways for molecular diagnostics within personalized medicine.
The publication of the report is scheduled for March 2021.
The full details in Dutch can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).